Aurora Cannabis’s Reliva Expands Portfolio with New CBD Brand, KG7

3.5 min readPublished On: February 4th, 2022By

EDMONTON, AB – Reliva, an American CBD brand and subsidiary of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced the launch of KG7, a new high-quality CBD product line developed for adult consumers with an active lifestyle. KG7 and Reliva products are available for purchase at https://relivacbd.com/ and in convenience stores across the United States.

“We’re excited to introduce KG7 to the Reliva family of leading CBD products,” says Miguel Martin, Chief Executive Officer of Aurora Cannabis. “As part of Reliva’s portfolio expansion strategy, KG7 extends our brand into additional CBD market segments. With this product line, we expect to solidify Reliva’s position as the #1 CBD brand in brick and mortar channels.”

KG7’s lineup of CBD products includes delicious, pectin-based gummies made with natural flavors and colors; topical creams formulated with ingredients such as arnica and shea butter; and gluten-free CBD oil and drink mixes.

Standing by its zero THC policy, each batch of KG7 is made with 100% hemp-derived CBD isolate and is 100% free of THC. All KG7 products are independent lab-verified and traceable to provide the safest and heathiest hemp products for physically active individuals.

The KG7 product lineup includes:

KG7 CBD Gummies:
20mg & 50mg Gummies

KG7 CBD Topicals:
250mg Stick
300mg Cream
30mg Travel-size Cream Packet

KG7 CBD Oils:
500mg Mint CBD Oil

KG7 CBD Drink Mixes:
25mg Burst (grape flavor)
25mg Smash (citrus flavor)

Forward-looking Information

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of new products. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward looking statements are based on the opinions, estimates and assumptions of management in light of management’s experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora’s business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 27, 2021 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

(This information is primarily sourced from Aurora Cannabis Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: HCN News Team

The News Team at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!